SCHEMBL16935995

SCHEMBL16935995

CN(Cc1c(OCCNC(=O)OC(C)(C)C)ccc(F)c1Cl)c1ccn2ncc(C(=O)O)c2n1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 1/20 0.41
▸ NTRK1 P04629 7/20 0.38
▸ JAK2 O60674 4/20 0.38
▸ CKS1B P61024 1/20 0.37
▸ SKP1 P63208 1/20 0.37
▸ SKP2 Q13309 1/20 0.37
▸ CSNK2A1 P68400 2/20 0.36
▸ CSNK2A2 P19784 1/20 0.36
▸ TGFBR1 P36897 2/20 0.35
▸ ADORA3 P0DMS8 1/20 0.35
▸ ADORA2A P29274 1/20 0.35
▸ BRD4 O60885 1/20 0.33
▸ ACVR1B P36896 1/20 0.33
▸ ACVRL1 P37023 1/20 0.33
▸ IRAK4 Q9NWZ3 1/20 0.33
▸ PDK2 Q15119 1/20 0.33
▸ EGFR P00533 1/20 0.32
▸ ITK Q08881 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16936000 0.93 TGFBR1 (0.40) SCN9ANTRK1JAK2CKS1BSKP1
SCHEMBL16935968 0.85 TGFBR1 (0.40) NTRK1JAK2CSNK2A1CSNK2A2TGFBR1
SCHEMBL16936088 0.85 NTRK1 (0.44) SCN9ANTRK1JAK2CKS1BSKP1
SCHEMBL16936008 0.78 NTRK1 (0.43) SCN9ANTRK1JAK2TGFBR1ADORA3
SCHEMBL21046005 0.76 SCN9A (0.42) SCN9ACKS1BSKP1SKP2TGFBR1
SCHEMBL19875239 0.75 ADORA3 (0.46) SCN9ANTRK1JAK2CKS1BSKP1
SCHEMBL21229319 0.74 NTRK1 (0.43) NTRK1JAK2
SCHEMBL16946989 0.73 NTRK1 (0.40) SCN9ANTRK1JAK2TGFBR1ADORA3
SCHEMBL21046006 0.72 SCN9A (0.38) SCN9ACKS1BSKP1SKP2TGFBR1
SCHEMBL21045868 0.72 IRAK4 (0.41) NTRK1TGFBR1IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3572416-B1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES TURNING POINT THERAPEUTICS INC (US) 2022-09-21 — — EP disclosed
US-20200216465-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES TURNING POINT THERAPEUTICS INC (US) 2020-07-09 — — US disclosed
EP-3636649-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES Turning Point Therapeutics, Inc. (US) 2020-04-15 — — EP disclosed
EP-3636650-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES Turning Point Therapeutics, Inc. (US) 2020-04-15 — — EP disclosed
EP-3636648-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES Turning Point Therapeutics, Inc. (US) 2020-04-15 — — EP disclosed
EP-3097107-B1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES TP THERAPEUTICS INC (US) 2019-04-17 — — EP disclosed
US-10246466-B2 Diaryl macrocycles as modulators of protein kinases TP THERAPEUTICS, INC. (US) 2019-04-02 — — US disclosed
US-20170334929-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES Turning Point Therapeutics, Inc. 2017-11-23 — — US disclosed
US-20170334929-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES Turning Point Therapeutics, Inc. 2017-11-23 — — US disclosed
US-9714258-B2 Diaryl macrocycles as modulators of protein kinases TP THERAPEUTICS, INC. (US) 2017-07-25 — — US disclosed
US-9714258-B2 Diaryl macrocycles as modulators of protein kinases TP THERAPEUTICS, INC. (US) 2017-07-25 — — US disclosed
US-20170002023-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES TP THERAPEUTICS, INC. (US) 2017-01-05 — — US disclosed
US-20170002023-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES TP THERAPEUTICS, INC. (US) 2017-01-05 — — US disclosed
EP-3097107-A2 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES TP Therapeutics, Inc. (US) 2016-11-30 — — EP disclosed
WO-2015112806-A2 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES TP THERAPEUTICS, INC. (US) 2015-07-30 — — WO disclosed
WO-2015112806-A2 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES TP THERAPEUTICS, INC. (US) 2015-07-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334929-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES MAP3K20, LCK, MAP3K1 SCN9A 1671/4885NTRK1 1072/4885JAK2 60/4885
US-20200216465-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES MAP3K20, LCK, MAP3K1 SCN9A 1671/4885NTRK1 1072/4885JAK2 60/4885
US-10246466-B2 Diaryl macrocycles as modulators of protein kinases MAP3K20, LCK, MAP3K1 SCN9A 1671/4885NTRK1 1072/4885JAK2 60/4885
US-20170002023-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES MAP3K20, LCK, MAP3K1 SCN9A 1671/4885NTRK1 1072/4885JAK2 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback